Wayne Buchan's questions to SCYNEXIS (SCYX) leadership • Q1 2022
Question
On behalf of Louise Chen, Wayne Buchan from Cantor Fitzgerald asked about the competitive impact of Mycovia's recent approval, the nature of the relationship with the contract sales organization Amplity, and any existing distribution or market access challenges for BREXAFEMME.
Answer
President and CEO Dr. Marco Taglietti positioned BREXAFEMME as a unique, new class of drug with a favorable safety profile and an expected dual indication for treatment and prevention, differentiating it from competitors. He described the Amplity relationship as a flexible, fully dedicated sales force. Both Dr. Taglietti and Chief Commercial Officer Christine Coyne confirmed there were no significant distribution or market access issues, citing strong payer coverage and supply chain efficiency.